Cushing´s Disease Epidemiology in Sweden
30 de abril de 2019 actualizado por: Vastra Gotaland Region
National Swedish Study in Cushing´s Disease Incidence and Outcomes
The purpose of this study is to study since 1987 all patients diagnosed with CD in Sweden and determine their outcomes including mortality.
A secondary objective is to focus on patients in remission and identify determinants of their different outcomes.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
This study is a retrospective nationwide study of all patients in Sweden with diagnosis CD between 1987 and 2013 were baseline data at diagnosis, information about the different treatments and follow-up data is going to be obtained by reviewing patients' medical journals. This information as well as the exact diagnose criteria for each patient are going to be extracted by Endocrinologists in all University Hospitals in Sweden. An expert group at the Sahlgrenska University Hospital in Gothenburg will put together the data.By the use of the Swedish Personal Number, the investigators are going to obtain information about both patients' and background population co-morbidities which have been collected in the different Swedish Registers.
Primary aim:
To study mortality of CD in Sweden.
Secondary aims:
- To study the influence of CD on myocardial infarction
- To study the influence of CD on stroke
- To study the influence of CD on cancer
- To study the influence of CD on hip fracture risk
- To study incidence and prevalence of CD in Sweden.
Tipo de estudio
De observación
Inscripción (Actual)
502
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Vastra Gotaland Region
-
Gothenburg, Vastra Gotaland Region, Suecia, 413 45
- Sahlgrenska University Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
All adult patients with confirmed CD diagnosis in Sweden
Descripción
Inclusion Criteria:
- All patients registered with Cushing's Disease in Sweden since 1987 in the statistical database for in- and out-patients, at the Swedish National Board of Health and Welfare will be included in the study.
Exclusion Criteria:
- No
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Patients with verified Cushing's Disease
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mortality
Periodo de tiempo: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
If event (death) has been occured during the observation period.
Data obtained by the Swedish Cause Of Death Register (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
influence of Cushing's Disease on myocardial infarction
Periodo de tiempo: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (myocardial infarction) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on stroke
Periodo de tiempo: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (stroke) has been occured during the observation period.Data obtained by the Swedish Register of In- and Out-patient Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on cancer
Periodo de tiempo: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (cancer) has been occured during the observation period.Data obtained by the Swedish Register of Cancer Diagnoses (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
influence of Cushing's Disease on hip fracture risk
Periodo de tiempo: From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
If event (hip fracture) has been occured during the observation period.Data obtained by the Swedish Register of Hip Fractures (Swedish Board of Health and Welfare)
|
From date of diagnosis until the last day of December 2014 or date of death from any cause, whichever came first, assessed up to 20 years
|
|
incidence of Cushing's Disease in Sweden
Periodo de tiempo: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
|
prevalence of Cushing's Disease in Sweden
Periodo de tiempo: Assessed up to 20 years.
|
Validation of Data obtained by The Swedish Board of Health and Welfare by reviewing all patients' journals
|
Assessed up to 20 years.
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Gudmundur Johannsson, Professor, Vastra Gotaland Region, Sahlgrenska University Hospital
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de septiembre de 2013
Finalización primaria (Actual)
1 de abril de 2019
Finalización del estudio (Actual)
1 de abril de 2019
Fechas de registro del estudio
Enviado por primera vez
5 de diciembre de 2014
Primero enviado que cumplió con los criterios de control de calidad
23 de enero de 2015
Publicado por primera vez (Estimar)
29 de enero de 2015
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
3 de mayo de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
30 de abril de 2019
Última verificación
1 de abril de 2019
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Neoplasias Glandulares y Epiteliales
- Enfermedades del sistema endocrino
- Neoplasias de glándulas endocrinas
- Enfermedades hipotalámicas
- Hiperpituitarismo
- Enfermedades de la pituitaria
- Adenoma
- Neoplasias hipofisarias
- Adenoma hipofisario secretor de ACTH
- Hipersecreción pituitaria de ACTH
Otros números de identificación del estudio
- NSSCDIO
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
INDECISO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .